Cite
HARVARD Citation
Lam, C. et al. (2022). Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 145 (8), pp. 565-574. [Online].